Cardiac Resynchronization Therapy in Patients With Atrial Fibrillation. The CERTIFY Study (Cardiac Resynchronization Therapy in Atrial Fibrillation Patients Multinational Registry).

Maurizio Gasparini, Christophe Leclercq, Maurizio Lunati, Maurizio Landolina, Angelo Auricchio, Massimo Santini, Giuseppe Boriani, Barbara Lamp, Alessandro Proclemer, Antonio Curnis, Catherine Klersy, Francisco Leyva

Research output: Contribution to journal › Article

84 Citations (Scopus)

Abstract

Objectives: The purpose of this study is to determine whether, in patients with atrial fibrillation (AF) undergoing cardiac resynchronization therapy (CRT), atrioventricular junction ablation (AVJA) is associated with a better outcome than treatment with rate-slowing drugs. Background: Different trials have demonstrated that CRT is effective in treating heart failure (HF) patients who are in sinus rhythm (SR). No trials have addressed whether CRT confers similar benefits on AF patients, with or without AVJA. Methods: The clinical outcomes of CRT for patients with permanent AF undergoing CRT combined with either AVJA (n= 443) or rate-slowing drugs (n= 895) were compared with those of SR patients (n= 6,046). Results: Median follow-up was 37 months. Total mortality (6.8 vs. 6.1 per 100 person-years) and cardiac mortality (4.2 vs. 4.0) were similar for patients with AF+AVJA and patients in SR (both p= NS). In contrast, the AF+drugs group hada higher total and cardiac mortality than the SR group and the AF+AVJA group (11.3 and 8.1, respectively; p<0.001). On multivariable analysis, AF+AVJA had total mortality (hazard ratio [HR]: 0.93, 95% confidence interval [CI]: 0.74 to 1.67) and cardiac mortality (HR: 0.88, 95% CI: 0.66 to 1.17) similar to that of the SR group, independent of known confounders. The AF+drugs group, however, had a higher total mortality (HR: 1.52, 95% CI: 1.26 to 1.82) and cardiac mortality (HR: 1.57, 95% CI: 1.27 to 1.94) than both the SR group and the AF+AVJA group (both p<0.001). Conclusions: Long-term survival after CRT among patients with AF+AVJA is similar to that observed among patients in SR. Mortality is higher for AF patients treated with rate-slowing drugs.

Original languageEnglish
Pages (from-to)500-507
Number of pages8
JournalJACC: Heart Failure
Volume1
Issue number6
DOIs
Publication statusPublished - Dec 2013

Fingerprint

Cardiac Resynchronization Therapy
Atrial Fibrillation
Registries
Mortality
Confidence Intervals
Pharmaceutical Preparations
Heart Failure

Keywords

  • Ablation of atrioventricular junction
  • Atrial fibrillation
  • Cardiac resynchronization therapy
  • Heart failure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Cardiac Resynchronization Therapy in Patients With Atrial Fibrillation. The CERTIFY Study (Cardiac Resynchronization Therapy in Atrial Fibrillation Patients Multinational Registry). / Gasparini, Maurizio; Leclercq, Christophe; Lunati, Maurizio; Landolina, Maurizio; Auricchio, Angelo; Santini, Massimo; Boriani, Giuseppe; Lamp, Barbara; Proclemer, Alessandro; Curnis, Antonio; Klersy, Catherine; Leyva, Francisco.

In: JACC: Heart Failure, Vol. 1, No. 6, 12.2013, p. 500-507.

Research output: Contribution to journal › Article

Gasparini, M, Leclercq, C, Lunati, M, Landolina, M, Auricchio, A, Santini, M, Boriani, G, Lamp, B, Proclemer, A, Curnis, A, Klersy, C & Leyva, F 2013, 'Cardiac Resynchronization Therapy in Patients With Atrial Fibrillation. The CERTIFY Study (Cardiac Resynchronization Therapy in Atrial Fibrillation Patients Multinational Registry).', JACC: Heart Failure, vol. 1, no. 6, pp. 500-507. https://doi.org/10.1016/j.jchf.2013.06.003
Gasparini M, Leclercq C, Lunati M, Landolina M, Auricchio A, Santini M et al. Cardiac Resynchronization Therapy in Patients With Atrial Fibrillation. The CERTIFY Study (Cardiac Resynchronization Therapy in Atrial Fibrillation Patients Multinational Registry). JACC: Heart Failure. 2013 Dec;1(6):500-507. https://doi.org/10.1016/j.jchf.2013.06.003
Gasparini, Maurizio ; Leclercq, Christophe ; Lunati, Maurizio ; Landolina, Maurizio ; Auricchio, Angelo ; Santini, Massimo ; Boriani, Giuseppe ; Lamp, Barbara ; Proclemer, Alessandro ; Curnis, Antonio ; Klersy, Catherine ; Leyva, Francisco. / Cardiac Resynchronization Therapy in Patients With Atrial Fibrillation. The CERTIFY Study (Cardiac Resynchronization Therapy in Atrial Fibrillation Patients Multinational Registry). In: JACC: Heart Failure. 2013 ; Vol. 1, No. 6. pp. 500-507.
@article{bb445e1c68f747b79f565e8cca1c6500,
title = "Cardiac Resynchronization Therapy in Patients With Atrial Fibrillation. The CERTIFY Study (Cardiac Resynchronization Therapy in Atrial Fibrillation Patients Multinational Registry).",
abstract = "Objectives: The purpose of this study is to determine whether, in patients with atrial fibrillation (AF) undergoing cardiac resynchronization therapy (CRT), atrioventricular junction ablation (AVJA) is associated with a better outcome than treatment with rate-slowing drugs. Background: Different trials have demonstrated that CRT is effective in treating heart failure (HF) patients who are in sinus rhythm (SR). No trials have addressed whether CRT confers similar benefits on AF patients, with or without AVJA. Methods: The clinical outcomes of CRT for patients with permanent AF undergoing CRT combined with either AVJA (n= 443) or rate-slowing drugs (n= 895) were compared with those of SR patients (n= 6,046). Results: Median follow-up was 37 months. Total mortality (6.8 vs. 6.1 per 100 person-years) and cardiac mortality (4.2 vs. 4.0) were similar for patients with AF+AVJA and patients in SR (both p= NS). In contrast, the AF+drugs group hada higher total and cardiac mortality than the SR group and the AF+AVJA group (11.3 and 8.1, respectively; p<0.001). On multivariable analysis, AF+AVJA had total mortality (hazard ratio [HR]: 0.93, 95{\%} confidence interval [CI]: 0.74 to 1.67) and cardiac mortality (HR: 0.88, 95{\%} CI: 0.66 to 1.17) similar to that of the SR group, independent of known confounders. The AF+drugs group, however, had a higher total mortality (HR: 1.52, 95{\%} CI: 1.26 to 1.82) and cardiac mortality (HR: 1.57, 95{\%} CI: 1.27 to 1.94) than both the SR group and the AF+AVJA group (both p<0.001). Conclusions: Long-term survival after CRT among patients with AF+AVJA is similar to that observed among patients in SR. Mortality is higher for AF patients treated with rate-slowing drugs.",
keywords = "Ablation of atrioventricular junction, Atrial fibrillation, Cardiac resynchronization therapy, Heart failure",
author = "Maurizio Gasparini and Christophe Leclercq and Maurizio Lunati and Maurizio Landolina and Angelo Auricchio and Massimo Santini and Giuseppe Boriani and Barbara Lamp and Alessandro Proclemer and Antonio Curnis and Catherine Klersy and Francisco Leyva",
year = "2013",
month = "12",
doi = "10.1016/j.jchf.2013.06.003",
language = "English",
volume = "1",
pages = "500--507",
journal = "JACC: Heart Failure",
issn = "2213-1779",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Cardiac Resynchronization Therapy in Patients With Atrial Fibrillation. The CERTIFY Study (Cardiac Resynchronization Therapy in Atrial Fibrillation Patients Multinational Registry).

AU - Gasparini, Maurizio

AU - Leclercq, Christophe

AU - Lunati, Maurizio

AU - Landolina, Maurizio

AU - Auricchio, Angelo

AU - Santini, Massimo

AU - Boriani, Giuseppe

AU - Lamp, Barbara

AU - Proclemer, Alessandro

AU - Curnis, Antonio

AU - Klersy, Catherine

AU - Leyva, Francisco

PY - 2013/12

Y1 - 2013/12

N2 - Objectives: The purpose of this study is to determine whether, in patients with atrial fibrillation (AF) undergoing cardiac resynchronization therapy (CRT), atrioventricular junction ablation (AVJA) is associated with a better outcome than treatment with rate-slowing drugs. Background: Different trials have demonstrated that CRT is effective in treating heart failure (HF) patients who are in sinus rhythm (SR). No trials have addressed whether CRT confers similar benefits on AF patients, with or without AVJA. Methods: The clinical outcomes of CRT for patients with permanent AF undergoing CRT combined with either AVJA (n= 443) or rate-slowing drugs (n= 895) were compared with those of SR patients (n= 6,046). Results: Median follow-up was 37 months. Total mortality (6.8 vs. 6.1 per 100 person-years) and cardiac mortality (4.2 vs. 4.0) were similar for patients with AF+AVJA and patients in SR (both p= NS). In contrast, the AF+drugs group hada higher total and cardiac mortality than the SR group and the AF+AVJA group (11.3 and 8.1, respectively; p<0.001). On multivariable analysis, AF+AVJA had total mortality (hazard ratio [HR]: 0.93, 95% confidence interval [CI]: 0.74 to 1.67) and cardiac mortality (HR: 0.88, 95% CI: 0.66 to 1.17) similar to that of the SR group, independent of known confounders. The AF+drugs group, however, had a higher total mortality (HR: 1.52, 95% CI: 1.26 to 1.82) and cardiac mortality (HR: 1.57, 95% CI: 1.27 to 1.94) than both the SR group and the AF+AVJA group (both p<0.001). Conclusions: Long-term survival after CRT among patients with AF+AVJA is similar to that observed among patients in SR. Mortality is higher for AF patients treated with rate-slowing drugs.

AB - Objectives: The purpose of this study is to determine whether, in patients with atrial fibrillation (AF) undergoing cardiac resynchronization therapy (CRT), atrioventricular junction ablation (AVJA) is associated with a better outcome than treatment with rate-slowing drugs. Background: Different trials have demonstrated that CRT is effective in treating heart failure (HF) patients who are in sinus rhythm (SR). No trials have addressed whether CRT confers similar benefits on AF patients, with or without AVJA. Methods: The clinical outcomes of CRT for patients with permanent AF undergoing CRT combined with either AVJA (n= 443) or rate-slowing drugs (n= 895) were compared with those of SR patients (n= 6,046). Results: Median follow-up was 37 months. Total mortality (6.8 vs. 6.1 per 100 person-years) and cardiac mortality (4.2 vs. 4.0) were similar for patients with AF+AVJA and patients in SR (both p= NS). In contrast, the AF+drugs group hada higher total and cardiac mortality than the SR group and the AF+AVJA group (11.3 and 8.1, respectively; p<0.001). On multivariable analysis, AF+AVJA had total mortality (hazard ratio [HR]: 0.93, 95% confidence interval [CI]: 0.74 to 1.67) and cardiac mortality (HR: 0.88, 95% CI: 0.66 to 1.17) similar to that of the SR group, independent of known confounders. The AF+drugs group, however, had a higher total mortality (HR: 1.52, 95% CI: 1.26 to 1.82) and cardiac mortality (HR: 1.57, 95% CI: 1.27 to 1.94) than both the SR group and the AF+AVJA group (both p<0.001). Conclusions: Long-term survival after CRT among patients with AF+AVJA is similar to that observed among patients in SR. Mortality is higher for AF patients treated with rate-slowing drugs.

KW - Ablation of atrioventricular junction

KW - Atrial fibrillation

KW - Cardiac resynchronization therapy

KW - Heart failure

UR - http://www.scopus.com/inward/record.url?scp=84889021338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889021338&partnerID=8YFLogxK

U2 - 10.1016/j.jchf.2013.06.003

DO - 10.1016/j.jchf.2013.06.003

M3 - Article

VL - 1

SP - 500

EP - 507

JO - JACC: Heart Failure

JF - JACC: Heart Failure

SN - 2213-1779

IS - 6

ER -

Access to Document